Positive Quality Intervention: Management of Alpelisib (Piqray®) Induced Hyperglycemia

**Description:** This PQI is intended to address effective practices for the management of alpelisib induced hyperglycemia by focusing on a multidisciplinary approach.

**Background:** Alpelisib (in combination with fulvestrant) is indicated for the treatment of HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer in males and postmenopausal females following progression on or after an endocrine-based regimen. PIK3CA mutations are present in up to 40% of HR-positive, HER2-negative, primary and metastatic breast cancers. Hyperglycemia is an expected on-target effect of PI3K inhibition. The phase 3 SOLAR-1 trial evaluated the combination of alpelisib and fulvestrant versus fulvestrant alone in patients with HR-positive, PIK3CA-mutated, advanced breast cancer who had received prior endocrine therapy. Hyperglycemia was reported in 63.7% of patients treated with alpelisib including 33% with Grade 3 (FPG>250-500 mg/dL) and 3.9% with Grade 4 (Fasting Blood Glucose (FBG)>500 mg/dL) events. Increases in fasting blood glucose and hemoglobin A1C were more pronounced in patients who were diabetic or prediabetic at baseline, with 83% and 74% of these patients experiencing hyperglycemia when treated with alpelisib, respectively.

**PQI Process:** Upon receipt of alpelisib prescription
- Verify recommended starting dose for alpelisib in combination with fulvestrant: 300 mg by mouth once daily with food
- Evaluate patient medical history of diabetes and other risk factors that may contribute to treatment induced hyperglycemia (high BMI, age, concurrent medications)
- Ensure baseline labs including HbA1C and FBG and add alerts to the EMR
  - Repeat weekly for two weeks, then monthly, and as needed
  - If blood glucose is elevated it is recommended to optimize blood glucose prior to initiation
  - If hyperglycemia develops, discuss initiation of metformin dosing with the provider as well as dose interruption and reductions (see supplemental information)
  - Provide patient with the prescription for a home glucometer (new ICD-10 Code R09.65 Drug and Chemical induced diabetes mellitus with hyperglycemia) and counsel appropriately
  - Add a dietitian consult at the start of the treatment and provide Diet for Hyperglycemia handout
  - Add endocrinology referral note to alpelisib regimen which can be initiated at the point of need

**Patient-Centered Activities:**
- Provide Oral Chemotherapy Education (OCE) sheet
- Provide and discuss with the patient a Patient pocket-size card from the manufacturer for educational purposes for other healthcare providers caring for patient
- Consider developing a dietitian-based recommendations/handout for patients with hyperglycemia
- Recommend a use of glucometer for patients who cannot travel to weekly lab appointments

**IMPORTANT NOTICE:** NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual’s sole responsibility to seek guidance from a qualified healthcare professional. *Updated 12.19.23*
Supplemental Information:

**Metformin Dosing Guidance from SOLAR 1 Trial**

1. Initiate metformin at 500 mg by mouth once a day with food
2. Increase to 500 mg twice a day if tolerated
3. Increase to 500 mg in am and 1000 mg in pm if tolerated
4. Increase to 1000 mg twice a day if needed and tolerated. Do not exceed 2000 mg per day

*Evaluate a patient for renal and hepatic impairment prior to the start of metformin

**In SOLAR-1, 87% of patients who developed hyperglycemia were initially started on metformin followed by insulin sensitizers and DPP-4 inhibitors, in accordance with ADA recommendation

**Dose Modifications: Based on Monitoring of Fasting Plasma Glucose (FPG)**

- Grade 1 (FPG > ULN – 160 mg/dL): No dose adjustment; Initiate metformin
- Grade 2 (FPG > 160 – 250 mg/dL): Intensify antidiabetic therapy. Reduce by 1 level if no resolution of FPG ≤ 160 within 21 days
- Grade 3 (FPG > 250 – 500 mg/dL): Suspend alpelisib therapy. Intensify antidiabetic therapy and consider IV hydration and/or electrolyte replacement. Reduce by 1 level if no resolution of FPG ≤ 160 within 5 days. Discontinue treatment if no resolution of FPG ≤ 160 within 21 days
- Grade 4 (FPG > 500 mg/dL): Suspend alpelisib therapy. Intensify antidiabetic therapy and consider IV hydration and/or electrolyte replacement. If FPG decreases to ≤ 500 mg/dL after 24 hours, follow Grade 3 guidelines. If no resolution after 24 hours, discontinue therapy

**Alpelisib Dose Adjustment Levels:**

- Recommended starting dose of 300 mg by mouth once daily with food
- If 300 mg reduce to 250 mg once daily with food
- If 250 mg reduce to 200 mg once daily with food

**Reference:**

1. PIQRAY® Package Insert.
3. Academy of Nutrition and Dietetics. Carbohydrate Counting for People with Diabetes.
Diet for Hyperglycemia

Hyperglycemia occurs when your blood sugar is high. High blood sugar can occur when you have diabetes, pre-diabetes or when you are taking certain medications like steroids or Alpelisib (PIQRAY®).

You may need to limit the amount of carbohydrates in your diet. At mealtimes, limit carbohydrates to 1 serving or ¼ of your plate.

| Breads, crackers and cereals | 1 slice bread  
|                             | 4-6 small crackers  
|                             | ½ cup cooked cereal  
| Pasta, rice and grains      | ½ cup pasta or rice or quinoa  
| Starchy vegetables          | ¼ large baked potato (3 ounces)  
|                             | ½ cup corn or mashed potatoes  
| Beans and legumes           | ½ cup beans or peas  
| Milk, soymilk and yogurt    | 1 cup milk or soymilk  
|                             | ¾ cup (6 ounces) unsweetened yogurt or sweetened with a sugar-free sweetener  
| Fruits and fruit juices      | 1 cup or 1 small piece of fresh fruit  
|                             | ½ cup canned fruit (no sugar added)  
|                             | 17 small grapes  
|                             | 1 cup melon or berries  
|                             | 2 tablespoons dried fruit (no added sugar)  
| Sweets (cakes, cookies, candies, ice cream, jam or jelly) | 2-inch square cake (unfrosted)  
|                             | ½ cup ice cream or frozen yogurt  
|                             | 2 small cookies (¾ ounce)  
|                             | 1 tablespoon syrup, jam, jelly, table sugar or honey  

www.ncoda.org
Other quick tips to keep your blood sugar down

- Do not drink sugar sweetened beverages, including juices. Drink sugar-free beverages such as water, unsweetened tea and unsweetened coffee.

- Always include a protein food when you eat carbohydrates for better blood sugar control. Foods that contain protein are meats (chicken, turkey, fish, beef and pork) that are not breaded or fried, eggs, nuts, nut butters (without sugar added), cheese and cottage cheese.

- Choose higher quality carbohydrates that contain fiber like beans, whole grain breads and pastas, brown rice, quinoa etc.

Authors: Amy Ladendecker, MS, RD, CSO, LDN & Dana Ingoglia, RD, CSO, LDN of Florida Cancer Specialists & Research Institute

References:
1. Academy of Nutrition and Dietetics. Carbohydrate Counting for People with Diabetes. [Leaflet]

IMPORTANT NOTICE: NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warnings, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual’s sole responsibility to seek guidance from a qualified healthcare professional.